{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T01:48:44Z","timestamp":1785894524683,"version":"3.56.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,31]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hepatitis B virus (HBV) vaccination is essential in hemodialysis (HD) populations, yet seroprotection remains suboptimal. Inflammation-related hematologic indices are frequently used in clinical practice, but their ability to predict HBV vaccine response in HD patients is uncertain. We evaluated clinical and laboratory determinants of HBV vaccine response, with a focus on lipid-derived indices and inflammatory ratios.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this multicenter retrospective study, adult HD patients followed between 2015 and 2025 who received at least three doses of HBV vaccine and had available anti-HBs measurements were included (n\u00a0=\u00a0341). Vaccine response was defined as anti-HBs \u226510 IU\/L; non-response as &amp;lt;10 IU\/L. Neutrophil-to-lymphocyte (NLR), platelet-to-lymphocyte (PLR), monocyte-to-lymphocyte (MLR), neutrophil percentage-to-albumin ratio (NPAR), and lipid ratios (TG\/HDL, TC\/HDL, LDL\/HDL) were calculated. Additional analyses using percentile-based categorization of NPAR confirmed the absence of a significant association with vaccine response. Multivariable logistic regression and receiver operating characteristic analyses were performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After the primary vaccination series, seroprotection was 77.4% and increased to 88.6% after revaccination\/boosters; it declined to 78.3% at 1 year and 69.2% at 2 years. Non-responders were older and had higher triglyceride levels and lower HDL cholesterol levels. In contrast, inflammatory indices (NLR, PLR, MLR, and NPAR) did not differ significantly between groups. These indices also demonstrated limited discriminative ability for predicting vaccine response. In multivariable analysis, HDL cholesterol remained positively associated with vaccine response [odds ratio (OR): 1.046, 95% confidence interval (CI): 1.006\u20131.086, P\u00a0=\u00a0.022], and triglyceride levels were negatively associated with vaccine response (OR: 0.992, 95% CI: 0.984\u20130.999, P\u00a0=\u00a0.024). The TG\/HDL ratio showed borderline statistical significance (OR: 1.235, 95% CI: 0.983\u20131.551, P\u00a0=\u00a0.070), suggesting a potential but limited contribution to vaccine response prediction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In HD patients, hematologic inflammatory indices were not informative for HBV vaccine response, whereas an atherogenic lipid profile\u2014particularly lower HDL and higher triglycerides\u2014showed a consistent association. Lipid parameters may support risk stratification and tailored post-vaccination monitoring strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ckj\/sfag221","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:53:49Z","timestamp":1782867229000},"source":"Crossref","is-referenced-by-count":0,"title":["Lipid parameters but not inflammatory indices predict hepatitis B vaccine responses in hemodialysis patients"],"prefix":"10.1093","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-5087-7263","authenticated-orcid":false,"given":"Hilal","family":"Ekici","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases and Clinical Microbiology, Yozgat City Hospital , Yozgat ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arzu","family":"Mirza","sequence":"additional","affiliation":[{"name":"Ankara Provincial Directorate of Health, Public Health Services Presidency, Communicable Diseases Unit , Ankara ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevgi","family":"Baltac\u0131","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Clinical Microbiology, Sivas Numune Hospital , Sivas ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davut","family":"Eren","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Kayseri City Hospital , Kayseri ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feyza \u0130zci","family":"\u00c7etinkaya","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Clinical Microbiology, \u00c7ank\u0131r\u0131 State Hospital , \u00c7ank\u0131r\u0131 ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Ceylan","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Clinical Microbiology, Bak\u0131r\u00e7ay University \u00c7i\u011fli Training and Research Hospital , \u0130zmir ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cansel","family":"Da\u011fdelen","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Clinical Microbiology, Bak\u0131r\u00e7ay University \u00c7i\u011fli Training and Research Hospital , \u0130zmir ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00fcmeyye","family":"Ye\u015filda\u011f","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Clinical Microbiology, \u015e\u0131rnak \u0130dil State Hospital , \u015e\u0131rnak ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1159-5818","authenticated-orcid":false,"given":"S\u00fcmeyra","family":"Koyuncu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Kayseri City Hospital , Kayseri ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"2026080421112228300_bib1","doi-asserted-by":"publisher","first-page":"1369661","DOI":"10.3389\/fcimb.2024.1369661","article-title":"Exploring blood lipids\u2013immunity associations following HBV vaccination: evidence from a large cross-sectional study","volume":"14","author":"Yang","year":"2024","journal-title":"Front Cell Infect Microbiol"},{"key":"2026080421112228300_bib2","doi-asserted-by":"publisher","first-page":"1131373","DOI":"10.3389\/fmed.2023.1131373","article-title":"The relationship between triglyceride, cholesterol and lipoprotein levels and immune responses to hepatitis B vaccine","volume":"10","author":"Guo","year":"2023","journal-title":"Front Med"},{"key":"2026080421112228300_bib3","doi-asserted-by":"publisher","first-page":"554","DOI":"10.3390\/pathogens13070554","article-title":"Overview of hepatitis B vaccine non-response and associated B cell amnesia: a scoping review","volume":"13","author":"Bello","year":"2024","journal-title":"Pathogens"},{"key":"2026080421112228300_bib4","doi-asserted-by":"publisher","first-page":"e1874303X304324","DOI":"10.2174\/011874303X304324240529133609","article-title":"Comparison of factors affecting the immune response to hepatitis B vaccination in stage 5 CKD","volume":"17","author":"Light","year":"2024","journal-title":"TOUNJ"},{"key":"2026080421112228300_bib5","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1111\/liv.14939","article-title":"Immunogenicity and safety of HBAI20 hepatitis B vaccine in non-responders: double-blinded, randomised, controlled phase 2 trial","volume":"41","author":"Koc","year":"2021","journal-title":"Liver Int"},{"key":"2026080421112228300_bib6","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3390\/vaccines10010034","article-title":"Factors affecting response to HBV vaccine","volume":"10","author":"Chang","year":"2022","journal-title":"Vaccines"},{"key":"2026080421112228300_bib7","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/ckj\/sfab028","article-title":"Hepatitis B vaccination in patients with chronic kidney disease: immunogenicity, seroprotection and strategies to improve response","volume":"14","author":"Fabrizi","year":"2021","journal-title":"Clin Kidney J"},{"key":"2026080421112228300_bib8","first-page":"397","article-title":"Factors affecting effectiveness of vaccination against hepatitis B in hemodialysis patients: meta-analysis","volume":"82","author":"Eleftheriadis","year":"2014","journal-title":"Clin Nephrol"},{"key":"2026080421112228300_bib9","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/1471-2369-13-109","article-title":"Association of response to hepatitis B vaccination and survival in ESRD patients","volume":"13","author":"Lin","year":"2012","journal-title":"BMC Nephrol"},{"key":"2026080421112228300_bib10","doi-asserted-by":"publisher","first-page":"3935","DOI":"10.1093\/ndt\/gfs091","article-title":"Strategies to improve hepatitis B vaccine immunogenicity in end-stage renal disease","volume":"27","author":"Somi","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"2026080421112228300_bib11","first-page":"1721","article-title":"Serum albumin level as an indicator of response to hepatitis B vaccination in dialysis patients","volume":"8","author":"Ghamar-Chehreh","year":"2017","journal-title":"Caspian J Intern Med"},{"key":"2026080421112228300_bib12","doi-asserted-by":"publisher","first-page":"6336","DOI":"10.1016\/j.vaccine.2017.05.051","article-title":"Hepatitis B vaccines: WHO position paper\u2014July 2017","volume":"35","author":"World Health Organization","year":"2017","journal-title":"Vaccine"},{"key":"2026080421112228300_bib13","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.vaccine.2007.11.084","article-title":"Factors influencing response to hepatitis B vaccine","volume":"26","author":"Alavian","year":"2008","journal-title":"Vaccine"},{"key":"2026080421112228300_bib14","first-page":"286","article-title":"Effects of erythropoietin resistance on hepatitis B vaccine response in dialysis patients","volume":"20","author":"Afsar","year":"2016","journal-title":"Clin Exp Nephrol"},{"key":"2026080421112228300_bib15","first-page":"2077","article-title":"Influence of immune factors on HBV vaccine response","volume":"18","author":"Deng","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"2026080421112228300_bib16","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1093\/cid\/ciac281","article-title":"Immunogenic determinants of hepatitis B vaccine response in adults","volume":"75","author":"Fonzo","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026080421112228300_bib17","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1016\/j.vaccine.2021.05.017","article-title":"Correlates of HBV vaccine protection in adults","volume":"39","author":"Muhoza","year":"2021","journal-title":"Vaccine"},{"key":"2026080421112228300_bib18","first-page":"8457102","article-title":"Immunologic memory and response to hepatitis B vaccine","volume":"2022","author":"Lian","year":"2022","journal-title":"J Immunol Res"},{"key":"2026080421112228300_bib19","first-page":"455","article-title":"Cholesterol and immune response: mechanistic insights","volume":"59","author":"Ryan","year":"2018","journal-title":"J Lipid Res"},{"key":"2026080421112228300_bib20","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.it.2021.02.004","article-title":"HDL in immune modulation","volume":"42","author":"Pirillo","year":"2021","journal-title":"Trends Immunol"},{"key":"2026080421112228300_bib21","first-page":"67","article-title":"TG\/HDL as inflammatory marker in metabolic disease","volume":"19","author":"Sulaiman","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"2026080421112228300_bib22","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.vaccine.2011.11.086","article-title":"Vitamin D deficiency is associated with poor response to active hepatitis B immunisation in patients with chronic kidney disease","volume":"30","author":"Zitt","year":"2012","journal-title":"Vaccine"},{"key":"2026080421112228300_bib23","volume-title":"Advisory Committee on Immunization Practices; Centers for Disease Control and Prevention (U.S.). Guidelines for vaccinating dialysis patients and patients with chronic kidney disease: recommendations of the Advisory Committee on Immunization Practices. Atlanta, GA: Centers for Disease Control and Prevention;","author":"Chi","year":"2012"},{"key":"2026080421112228300_bib24","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1093\/ndt\/11.8.1559","article-title":"Response to the hepatitis B virus vaccine in haemodialysis patients: influence of malnutrition and its importance as a risk factor for morbidity and mortality","volume":"11","author":"Fern\u00e1ndez","year":"1996","journal-title":"Nephrol Dial Transplant"},{"key":"2026080421112228300_bib25","doi-asserted-by":"publisher","first-page":"913","DOI":"10.4161\/hv.7.9.16225","article-title":"Rapid, enhanced, and persistent protection of patients with renal insufficiency by AS02(V)-adjuvanted hepatitis B vaccine","volume":"7","author":"Surquin","year":"2011","journal-title":"Hum Vaccines"},{"key":"2026080421112228300_bib26","doi-asserted-by":"publisher","first-page":"2541873","DOI":"10.1080\/0886022X.2025.2541873","article-title":"Optimizing hepatitis B vaccination in chronic kidney disease: a comprehensive scoping review of strategies across CKD stages, dialysis, and transplant populations","volume":"47","author":"Chancharoenthana","year":"2025","journal-title":"Ren Fail"},{"key":"2026080421112228300_bib27","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.ekir.2024.01.014","article-title":"A randomized controlled study of efficacy and safety of accelerated versus standard hepatitis B vaccination in patients with advanced CKD","volume":"9","author":"Kittrakulrat","year":"2024","journal-title":"Kidney Int Rep"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfag221\/68665145\/sfag221.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/8\/sfag221\/68665145\/sfag221.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/8\/sfag221\/68665145\/sfag221.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T01:11:31Z","timestamp":1785892291000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfag221\/8722922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,7,31]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfag221","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,7,1]]},"article-number":"sfag221"}}